Introduction
Frontotemporal degeneration (FTD) is a common form of dementia, especially in individuals less than 65 years of age at time of diagnosis. FTD typically comprises three distinct clinical syndromes: behavioral variant frontotemporal degeneration (bvFTD), and two primary progressive aphasias (PPA): semantic variant primary progressive aphasia (svPPA) and a nonfluent variant primary progressive aphasia (nfvPPA). There are also three other neurodegenerative syndromes that frequently overlap both clinically and neuropathologically with FTD: corticobasal syndrome (CBS), progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS) [1••] .
Diagnostic criteria for these syndromes have been proposed before and seminal features of each syndrome include social dysfunction, executive and behavioral changes for bvFTD [2] , early semantic knowledge loss for svPPA, and motor speech deficits for nfvPPA [3] . New diagnostic criteria with multiple subtypes for CBS were recently proposed [4] . PSP is defined by early falls, ophthalmoplegia although subtypes exist [5, 6] , while ALS is a motor neuron disease with increasingly recognized cognitive dysfunction [7, 8] . Each syndrome can be associated with one or more underlying neuropathological diagnoses that are referred together under the umbrella term frontotemporal lobar degeneration (FTLD). The most common underlying neuropathologies in FTLD involve deposition of tau protein (FTLD-tau) or TAR DNA binding protein 43 kDa (TDP-43; FTLD-TDP) [9] .
Thus, it is clear that FTD is a diverse neurodegenerative syndrome with a heterogeneous clinical presentation. Although there are no United States Food and Drug Administration (FDA) approved therapies for FTD (except riluzole for ALS), for symptomatic management it may be helpful to group FTD symptoms into cognitive, behavioral, and motor domains. Currently used treatments are mostly off-label medications for symptomatic management and have minimal evidence from randomized, placebo-controlled trials to support their use. These therapies rely on modulation of neurotransmitter levels and do not target the underlying pathophysiology of FTD. Three factors have historically contributed to the difficulty of conducting adequately powered, placebo-controlled trials that provide the highest level of evidence. They are the limited number of cases of FTD (it is a rare disease), the heterogeneous presentations of FTD and the diverse underlying pathology for the range of FTD syndromes. Cost inexpensive Standard dosage starting at 1.5 mg twice a day, titrate to 6 mg twice a day. Transdermal patch starts with 4.6 mg per 24 h, increased to 13.3 mg per 24 h after 4 weeks.
Treatment
Contraindications caution in patients with bradycardia, cardiac conduction disorder, severe obstructive pulmonary disease, peptic ulcer disease; caution when used with betablockers
Main drug interactions beta-blockers, antagonistic effects with anticholinergics
Main side effects nausea, diarrhea, insomnia, fatigue, vomit, cramps, vivid dreams, bradycardia
Cost inexpensive, transdermal system may be slightly more expensive [39] . There is now a black-box warning for all antipsychotics as the FDA determined the use of atypical antipsychotics for dementia-related behavioral symptoms to be associated with higher mortality than placebo, related to heart or infection events. & In FTD patients with severe behavioral disturbances who invariably require an antipsychotic, 2nd or 3rd generation antipsychotics with less extrapyramidal side effects are preferred. As quetiapine has a more favorable side effect profile, especially in movement disorder patients, it may be an appropriate initial therapy [Class I] [40•]. The increased mortality and side effects with antipsychotics must ultimately be weighed against the potential benefits to quality of life an antipsychotic may provide. As caring for FTD patients is known to be extremely burdensome, the potential benefits may be largest for caregivers of patients with violent or disruptive behaviors [41] .
Standard dosage oral 25 mg daily to maximum 400 mg daily divided by two or three times a day dosing 
Cost expensive compared to other oral agents
Anti-epileptic agents
& Anti-epileptic agents have been used as mood stabilizers for manic behaviors, but none have been studied rigorously in the treatment of FTD. & Anti-epileptics with mood-stabilizing effects such as carbamazepine and valproic acid were reported to improve behavioral symptoms [Class IV] [30, 44] . However, chronic valproic acid use has also been studied in Alzheimer's population and showed increased brain atrophy [45] . & Topiramate is an anti-epileptic with a migraine treatment indication, mood-stabilizing effects, and also a propensity to cause anorexia. Interestingly, in several case reports it has been shown to reduce hyper-orality in FTD patients [Class IV] [46] [47] [48] [49] . & Overall, there is lack of quality evidence to recommend routine use of antiepileptic agents for mood stabilization. This class of medication has significant side effects that must be weighed against its potential benefits to patient and caregiver quality of life.
Standard dosage oral 200 mg to 800 mg twice to three times daily
Contraindications concomitant MAOi use, concomitant use of nonnucleoside reverse transcriptase inhibitors, hypersensitivity to tricyclic antidepressants (TCA), bone marrow depression; avoid abrupt withdrawal
Main drug interactions medications associated with CYP1A2, 2B6, 2C, 3A4 pathways as carbamazepine is an inducer.
Main side effects rash, myelosuppresion, hepatitis, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), pancreatitis, congenital malformations, seizures, dizziness, drowsiness, blurred vision, impaired coordination
Special points carbamazepine is a significant inducer of its own metabolism and serum levels may decrease after chronic use
Cost inexpensive Standard dosage 25 mg to 200 mg daily or twice daily
Contraindications avoid abrupt withdrawal

Main drug interactions carbonic anhydrase inhibitors, oral contraceptives
Main side effects metabolic acidosis, nephrolithiasis, osteoporosis, hypokalemia, rash, glaucoma, paresthesias, weight loss, somnolence, cognitive dysfunction
Special points topiramate has significant cognitive dysfunction side effects, regular ophthalmological exam for glaucoma recommended
Oxytocin
& The neuropeptide oxytocin is not only delivered to the pituitary gland, but also to regions of the CNS including the amygdala, nucleus accumbens, and prefrontal cortex where it is thought to play a role in regulating social behavior. A randomized, double-blind, placebo-controlled study examined the effects of a single dose of 24 IU intranasal oxytocin in 20 bvFTD patients . The study demonstrated improvements in NPI via small reductions across multiple items and reduced identification of negative facial expressions, a possible sign of improved cooperative behavior. There was a trend towards improvement in a caregiver burden scale. Further trials with repeated dosing, more patients, and longer follow-up will be needed to validate efficacy of this novel use of oxytocin to treat the symptoms of bvFTD [50] .
Pharmacologic treatment of motor symptoms
& The relationship between motor neuron disease (amyotrophic lateral sclerosis; ALS) and FTD is increasingly recognized with up to 15 % of FTD patients displaying signs of motor neuron disease [51] . In 2011, a hexanucleotide repeat expansion in a 5' non-coding region of the C9ORF72 gene was found to be responsible for a large percentage of familial FTD-ALS syndromes [52] [53] [54] . Riluzole is currently the only FDA approved disease modifying treatment for ALS after two landmark trials [55, 56] . & Although a large PSP trial using davunetide, a growth factor activitydependent neurotrophic protein-derived peptide thought to stabilize microtubules, failed to demonstrate efficacy [67••] , new microtubule stabilizing agents continue to be explored as possible treatments [68] . & A number of strategies to block the expression of C9ORF72 hexanucleotide repeat expansions including antisense oligonucleotides and other small molecules seem particularly promising for this most common genetic cause of FTD [69, 70] .
